Phathom Pharmaceuticals Inc. announced the publication of new data from its Phase 3 pHalcon-NERD-301 clinical trial evaluating VOQUEZNA® (vonoprazan) tablets in patients with Non-Erosive Reflux Disease $(NERD)$. The results, published in the American Journal of Gastroenterology, demonstrated that VOQUEZNA provided rapid and sustained relief of nighttime gastroesophageal reflux disease (GERD) symptoms. Patients treated with VOQUEZNA showed clinically meaningful increases in heartburn-free nights after the first dose, with these effects maintained through 24 weeks of treatment. The study found that, at week 4, mean percentages of heartburn-free nights were 59.9% and 56.4% for the 10 mg and 20 mg VOQUEZNA doses respectively, compared to 43.3% for placebo. The publication adds to the clinical evidence for VOQUEZNA in addressing nocturnal GERD symptoms.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Phathom Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9552067-en) on October 25, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.